Calcium carbonate powder as a phosphate binder

Area of Science:

• Nephrology
• Clinical Pharmacy
• Internal Medicine

Background:

• Aluminum hydroxide, a traditional phosphate binder, presents significant drawbacks.
• Calcium carbonate is now preferred but carries a risk of hypercalcemia.
• The efficacy and safety of calcium carbonate in powdered form require further investigation.

Purpose of the Study:

• To evaluate the efficacy of calcium carbonate powder as a phosphate binder in end-stage renal disease (ESRD) patients.
• To determine the frequency of hypercalcemia associated with calcium carbonate powder use.
• To assess the impact of powdered calcium carbonate on phosphate and calcium levels.

Main Methods:

• Twenty-one ESRD patients were switched from other phosphate binders to calcium carbonate powder (CalCarb-HD).
• Dosage was adjusted to maintain serum phosphorus between 3.5-5.5 mg/dL and calcium below 11.5 mg/dL.
• Patient outcomes, including calcium and phosphorus levels and hypercalcemia episodes, were monitored over seven months.

Main Results:

• After seven months, average calcium levels were 9.9 mg/dL and phosphorus levels were 5.5 mg/dL.
• Only two episodes of hypercalcemia (calcium > 11.5 mg/dL) were recorded across all patients.
• Average daily calcium dose increased from 1.4 to 1.8 packets/day over the study period.

Conclusions:

• Calcium carbonate powder is an effective phosphate binder for ESRD patients.
• The powdered form may lead to enhanced bioavailability, contributing to a low incidence of hypercalcemia.
• This formulation offers a potentially safer alternative for phosphate management in renal disease.